NCT07385300

Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis

Evaluation of the Use of Omega-3 Pufa and Aspirin as Adjunctive Therapy in the Treatment of Smoker Patients With Stage Iii Periodontitis (Randomized Clinical Trial)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 35 Years
• Healthy volunteers: Not accepted

Summary

Background: Smoking reduces the effect of non-surgical periodontal therapy, a host modulation regimen consisting of omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation with low-dose aspirin (ASA) with or without systemic doxycycline has been proposed to improve treatment response. The Aim of the study is to explore the clinical effects of orally administered omega-3 PUFA and ASA with or without systemic doxycycline with periodontal debridement in treatment of smoker individuals with stage III periodontitis.

Conditions

• Periodontitis
• Diabete Mellitus

Interventions

Type	Name	Description
OTHER	Omega-3 PUFA and Aspirin as adjunctive therapy to (SRP)	fifteen patients will receive ω-3 PUFA + ASA (1g of fish oil/day + 75mg ASA/day for 2 months) after periodontal debridement (TG1)
OTHER	Omega-3 PUFA and Aspirin and doxycycline as adjunctive therapy to (SRP)	fifteen patients will receive ω-3 PUFA + ASA (1g of fish oil/day + 75mg ASA/day for 2 months) and oral dosage of doxycycline (100mg every 12 hours on day 1, then 100 mg once daily for 6 days) after periodontal debridement (TG2)
OTHER	scaling and root planning (SRP)	fifteen patients will receive periodontal debridement (CG)

Timeline

• Start date: 2023-08-20
• Primary completion: 2024-08-22
• Completion: 2024-08-22
• First posted: 2026-02-04
• Last updated: 2026-02-04

Locations

1 site across 1 country: Egypt